Revefenacin

/Tag:Revefenacin

EFFICACY AND SAFETY OF REVEFENACIN IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IS NOT AGE DEPENDENT: A POST HOC SUBGROUP ANALYSIS OF THREE PHASE 3 TRIALS

Background: Revefenacin (REV), a once-daily, long-acting muscarinic antagonist for nebulized inhalation, was recently approved for maintenance treatment of chronic obstructive pulmonary disease (COPD). We present post hoc efficacy and safety data from three phase 3 [...]

By | 2019-03-11T14:18:44+00:00 March 11th, 2019|Hospital Medicine 2019, Other, Research|Comments Off on EFFICACY AND SAFETY OF REVEFENACIN IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IS NOT AGE DEPENDENT: A POST HOC SUBGROUP ANALYSIS OF THREE PHASE 3 TRIALS

PREVALENCE AND PREDICTORS OF SUBOPTIMAL PIFR ACROSS GOLD STAGES: ANALYSES FROM THE REVEFENACIN PHASE 3 PROGRAM

Background: Many patients with chronic obstructive pulmonary disease (COPD) have suboptimal peak inspiratory flow rate (sPIFR) because of lung hyperinflation, hypoxemia, and muscle wasting, preventing effective use of dry powder inhalers commonly used to treat [...]

By | 2019-03-11T14:18:46+00:00 March 11th, 2019|Hospital Medicine 2019, Other, Research|Comments Off on PREVALENCE AND PREDICTORS OF SUBOPTIMAL PIFR ACROSS GOLD STAGES: ANALYSES FROM THE REVEFENACIN PHASE 3 PROGRAM

Revefenacin, an Investigational Long-acting Muscarinic Antagonist for Nebulization: Pooled Results of Replicate Phase 3 Trials in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Background: Currently, once-daily nebulized bronchodilator therapy is unavailable for patients with chronic obstructive pulmonary disease (COPD). Prior studies demonstrated that once-daily revefenacin (REV) doses of 88 and 175 µg produced significant bronchodilation in COPD patients. [...]

By | 2018-03-19T13:14:25+00:00 March 19th, 2018|Hospital Medicine 2018, Research, Translating Research into Practice|Comments Off on Revefenacin, an Investigational Long-acting Muscarinic Antagonist for Nebulization: Pooled Results of Replicate Phase 3 Trials in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease